At first, Krista Easom figured the little red bump on her foot was nothing more than a blister.
It didn’t hurt, but after a couple months, it didn’t go away either.
She booked an appointment with a dermatologist to have it removed. She wasn’t worried. Easom, a 24-year-old law school student from New Jersey, was healthy, had no family history of cancer and was getting ready to enjoy some time in her newly adopted city of Chicago.
That’s when she received the results from her dermatologist, who removed a part of the blister and had it tested.
It turns out that little red bump was malignant melanoma, the leading cause of skin cancer death in the United States. It’s a cancer that kills one person every hour, which translates to more than 8,700 Americans each year.
Further tests revealed that Easom’s melanoma had spread to her lymph nodes, which meant she needed a lymphadenectomy to have them removed. This major surgery includes a five-day stay in the hospital followed by an extensive recovery. About half of the patients who undergo this procedure suffer from wound infections because of the 12-inch incision’s hip-to-thigh location.
Easom and her family looked into her options and she was referred to Northwestern Medicine® surgical oncologists Jeffery D. Wayne, MD and Karl Bilimoria, MD, two of the very few surgeons in the country using a minimally invasive procedure to remove groin lymph nodes. This laparoscopic procedure may drastically reduce the recovery rate and chance of infection for patients like Easom.
“Only a handful of surgeons in the country are doing this and it makes a world of difference to the patient,” said Bilimoria, a surgical oncologist at Northwestern Memorial Hospital and an assistant professor of surgery at Northwestern University Feinberg School of Medicine. “Instead of a 12-inch scar, this laparoscopic procedure has only three very small incisions that total less than one inch. Because these incisions are so small, the chance of infection is far less. Instead of a five-day stay in the hospital, Krista went home the day after her surgery.”
Lymph nodes are the most frequent site of the spread of metastatic melanoma and surgically removing them is the only potential for a cure, Wayne said.
“Surgery is the only way to make sure we get all of the cancer,” Wayne said. “We want Krista to move on with her life. The minimally-invasive procedure was by far, the quickest and safest way for her to do that.”
Just a few weeks post-surgery, Easom is already on her way. She will have regular check-ups for awhile but her CT scans and blood tests show that the surgery successfully removed all of her cancer. Easom is participating in a national clinical trial to see if this minimally invasive procedure can help other melanoma patients.
The Latest on: Melanoma
- US Melanoma Market Expected to Show Enthralling Growth of 8.3 % CAGR to Reach USD 2.4 Million by 2023 on September 20, 2018 at 7:38 pm
Pune, India -- (SBWIRE) -- 09/20/2018 -- US melanoma market has been segmented on the basis of type (superficial spreading, nodular, lentigo maglina, acral lentigious and others), by gender (male and ... […]
- Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma on September 20, 2018 at 5:00 pm
CASTRES, France--(BUSINESS WIRE)--Pierre Fabre today announced that the European Commission (EC) has granted marketing authorisation for the combination of BRAFTOVI® (encorafenib) and MEKTOVI ... […]
- Online melanoma test could save your life on September 20, 2018 at 2:26 pm
GOLD Coast-based author Mandy Johnson always thought she was at low risk of developing melanoma until she took a simple online test developed by Queensland researchers. She was shocked to discover she ... […]
- Binimetinib/Encorafenib Combo Approved in Europe for BRAF+ Melanoma on September 20, 2018 at 1:33 pm
The European Commission has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of adult patients with BRAF V600–mutant ... […]
- European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma on September 20, 2018 at 11:22 am
- European Commission approval applies to all 28 European Union member states, Liechtenstein, Iceland and Norway - - Approval is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months ... […]
- Galectin up 11% premarket on positive early-stage data on GR-MD-02 in melanoma on September 20, 2018 at 9:53 am
Galectin Therapeutics (NASDAQ:GALT) is up 11% premarket on average volume on the heels of its announcement of preliminary data from a Phase 1b clinical trial evaluating GR-MD-02, combined with ... […]
- Chicago Scene: Preview of the upcoming Wings of Hope for Melanoma gala on September 20, 2018 at 9:31 am
To raise awareness for melanoma and The Melanoma Research Foundation and the upcoming Wings of Hope for Melanoma Chicago, being held September 26 th at Morgan Manufacturing (401 N. Morgan Street ... […]
- Prognostic Value of Low Tumor Burden in Patients With Melanoma on September 18, 2018 at 10:12 am
The therapeutic landscape for cutaneous melanoma has dramatically advanced in the last several years with the development, validation, and approval by the US Food and Drug Administration of several ne... […]
- Emerging Combination Regimens in Advanced Melanoma on September 18, 2018 at 9:46 am
Jeffrey S. Weber, MD, PhD: Let’s move on, because we still have a few things to discuss. Omid, what other combinations are you excited about? I was told that there are a thousand immunotherapy combina... […]
- Toward an 'ultra-personalized' therapy for melanoma on September 12, 2018 at 5:40 pm
With new immunotherapy treatments for melanoma, recovery rates have risen dramatically, in some cases to around 50 percent. But they could be much higher: A new study shows, in lab dishes and animal s... […]
via Google News and Bing News